Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508948 | 0.93 | SMN1; SMN2 (0.62) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL17162119 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL21070867 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL23043307 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTLMNAASAH1 | |
| SCHEMBL29025356 | 0.86 | EPHX2 (0.57) | SMN1; SMN2HTTLMNATSHRL3MBTL1 | |
| SCHEMBL8914641 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL18626198 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL7332230 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL8604263 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTLMNAASAH1TSHR | |
| SCHEMBL1577945 | 0.84 | SMN1; SMN2 (0.75) | SMN1; SMN2HTTLMNAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-102329267-A | 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists | LILLY CO ELI | 2012-01-25 | — | — | CN | disclosed |
| CN-102311387-A | 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists | LILLY CO ELI | 2012-01-11 | — | — | CN | disclosed |
| EP-1513524-A4 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1824863-A1 | SILICON COMPOUNDS AND THEIR USE | Takeda Cambridge Limited (GB) | 2007-08-29 | — | — | EP | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| WO-2006064277-A1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-1513524-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003103584-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CPSF6, NFATC1, CPSF1 | SMN1; SMN2 3976/4885HTT 4139/4885LMNA 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.